← back to search

Wayne Tam

Donald & Barbara Zucker School of Medicine at Hofstra/Northwell ·
Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, and Acute Myeloid Leukemia Research.
h-index
54
citations
15,140
works
343
NIH funding
primary concept
email

Recent publications

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities
Cell Reports Medicine 2025cited by 8position: middledoi
Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas
Nature Materials 2023cited by 44position: middledoi
Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group
Leukemia Research 2023cited by 16position: middledoi
Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group
JCO Precision Oncology 2023cited by 13position: middledoi
Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in <i>IGH-BCL2</i> + diffuse large B-cell lymphomas
Blood 2021cited by 42position: middledoi
Myeloid/lymphoid neoplasms with FLT3 rearrangement
Modern Pathology 2021cited by 40position: middledoi
Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group
Modern Pathology 2021cited by 17position: middledoi
Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression
Life Science Alliance 2020cited by 71position: middledoi
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing
Nature Cancer 2020cited by 69position: middledoi
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
Journal of Hematology & Oncology 2020cited by 56position: middledoi
Somatic mutations and cell identity linked by Genotyping of Transcriptomes
Nature 2019cited by 330position: middledoi
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
Cancer Immunology Research 2019cited by 177position: middledoi
Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia
Leukemia & lymphoma/Leukemia and lymphoma 2019cited by 29position: middledoi
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Blood 2018cited by 200position: middledoi
TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis
Cancer Discovery 2018cited by 164position: middledoi
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma
Blood 2018cited by 122position: middledoi
Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study
Modern Pathology 2018cited by 58position: middledoi
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome
Haematologica 2017cited by 77position: middledoi
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia
Modern Pathology 2017cited by 73position: middledoi
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells
Cancer Discovery 2017cited by 49position: middledoi
<i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
Cancer Discovery 2016cited by 269position: middledoi
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells
Cell 2016cited by 242position: middledoi
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
Journal of Clinical Investigation 2016cited by 172position: middledoi
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified
Modern Pathology 2016cited by 127position: middledoi
Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care
npj Genomic Medicine 2016cited by 88position: middledoi
Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)
Blood 2016cited by 9position: middledoi
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development
Nature Medicine 2015cited by 442position: middledoi
Epigenomic evolution in diffuse large B-cell lymphomas
Nature Communications 2015cited by 128position: middledoi
The tumor virus landscape of AIDS-related lymphomas
Blood 2015cited by 87position: middledoi
EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis
Leukemia 2015cited by 77position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Olivier Elemento · Cornell University8 papers (2014–2020)Daniel A. Arber · University of Illinois Chicago7 papers (2016–2023)Sa A. Wang · Western Oncolytics (United States)7 papers (2016–2023)Adam Bagg · Abramson Cancer Center7 papers (2016–2023)Robert P. Hasserjian · Harvard University7 papers (2016–2023)Attilio Orazi · Providence Hospital7 papers (2016–2023)Heesun J. Rogers · Cleveland Clinic6 papers (2016–2023)Eric D. Hsi · Mayo Clinic6 papers (2016–2023)Kathryn Foucar · University of New Mexico5 papers (2016–2023)Ari Melnick · Cornell University5 papers (2013–2017)John P. Leonard · NYU Langone Health5 papers (2012–2018)Leandro Cerchietti · Cornell University5 papers (2013–2018)Giorgio Inghirami · Cornell University4 papers (2013–2020)Carlos E. Bueso‐Ramos · The University of Texas MD Anderson Cancer Center4 papers (2016–2021)Rita Shaknovich · Meta (United States)3 papers (2013–2016)Kui Nie · Inner Mongolia University of Science and Technology3 papers (2014–2021)Tracy I. George · University of Utah3 papers (2016–2021)Yanwen Jiang · University College London3 papers (2014–2017)Olga K. Weinberg · Boston Children's Hospital3 papers (2018–2023)Peter Martin · Griffith University3 papers (2013–2018)